Tuesday, November 13, 2012
SCHOFIELD, Wis., November 13, 2012 – PuraMed BioScience®
, Inc,. (OTCQB: PMBS) announces that its homeopathic migraine formulation, LipiGesic® M
, has been recognized as an excellent first-line therapy in the treatment for acute migraine. The declaration was made in the online article “Advances in Drug Development for Acute Migraine,” [page 14]
scheduled for publication in an upcoming printed issue of Drugs
, a medical journal evaluating drugs and drug therapies read by over 500,000 healthcare providers.
Authors Ryan J. Cady, Candace L. Shade, and Roger K. Cady, MD
, reviewed 11 drugs, which are considered advancements in acute migraine treatment. LipiGesic M was the only product described as “an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options.”
“With this ‘excellent first-line therapy’
designation, consumers can be assured that headache experts have reviewed the clinical study evidence for LipiGesic M’s efficacy and have determined that LipiGesic M is the first medication sufferers should take to relieve migraine pain and migraine associated symptoms,” said Russell Mitchell, president and CEO of PuraMed BioScience.
LipiGesic M is an over-the-counter, homeopathic formulation of feverfew and ginger delivered in a sublingual (under-the-tongue) gel for the acute treatment of migraine. Sublingual delivery preserves the effectiveness of the active ingredients since they are absorbed directly into the blood stream bypassing the digestive system where breakdown occurs.
“Migraine sufferers are looking for relief, but many current treatments produce severe and often debilitating side effects,” said Mitchell. “Our non-drowsy formulation can relieve migraine headaches without medication hangover symptoms at a fourth of the cost of the top-selling prescription treatments. Inclusion in the article as the only over-the-counter product in the advancement of acute migraine treatment with the advantages of lower cost and little to no risk of medication overuse or rebound headaches is encouraging.
“This article and the results of the soon-to-be-completed LipiGesic M children’s study are significant milestones as we continue to build awareness within both the medical and consumer markets,” said Mitchell.
Currently, LipiGesic M is available at both Walgreens and CVS/pharmacy stores. One box of LipiGesic M typically treats four headaches at a cost of approximately $5 per treatment.
About PuraMed BioScience®, Inc.:
PuraMed BioScience, Inc. engages in the research, development, and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®
M, a sublingual acute treatment for the relief of migraine headaches, which was published in the top-tier medical journal, Headache: The Journal of Head and Face Pain
M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic®
M, the Company also has plans to launch LipiGesic®
H for tension-type headaches as well as LipiGesic®
PM, which provides a remedy for insomnia and other sleep disorders.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
Product Website: www.lipigesic.com
Corporate Website: www.puramedbioscience.com